Innova Captab Limited (NSE:INNOVACAP)

Market Cap	56.62B +18.4%
Revenue (ttm)	16.30B +31.1%
Net Income	1.41B +9.9%
EPS	24.63 +9.9%
Shares Out	57.22M
PE Ratio	40.18
Forward PE	29.80
Dividend	3.00 (0.30%)
Ex-Dividend Date	Jan 30, 2026

Volume	65,353
Open	993.00
Previous Close	990.85
Day's Range	985.05 - 1,012.60
52-Week Range	622.00 - 1,033.80
Beta	-0.05
Analysts	Strong Buy
Price Target	1,078.50 (+8.94%)
Earnings Date	Jul 24, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INNOVACAP

Financial Performance

In fiscal year 2026, Innova Captab's revenue was 16.30 billion, an increase of 31.06% compared to the previous year's 12.44 billion. Earnings were 1.41 billion, an increase of 9.87%.

Analyst Summary

According to 2 analysts, the average rating for INNOVACAP stock is "Strong Buy." The 12-month stock price target is ₹1,079, which is an increase of 8.94% from the latest price.

Price Target

₹1,079

(8.94% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error